Cantor Fitzgerald analyst Jennifer Kim downgraded Poseida Therapeutics (PSTX) to Neutral from Overweight without a price target after the company entered into a merger agreement to be acquired by Roche (RHHBY) at a price of $9.00 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX: